Jolt Capital

Jolt Capital, established in 2011 and headquartered in Paris, France, is a private equity firm specializing in growth equity investments. It focuses on mid-sized European technology companies, typically with revenues between €10 million and €100 million and maximum EBITDA of €40 million. Jolt Capital invests in these companies to finance working capital, capital expenditures, external growth strategies, and to strengthen their balance sheets. Its investment range is between €5 million and €40 million, with a preference for leading equity positions that may include a board seat or minority stakes. The firm's portfolio spans various technology sectors, including software, hardware, mobility, cloud, IoT, cybersecurity, and digital health, among others. Jolt Capital is led by Jean Schmitt and an experienced team, aiming to catalyze growth and operational efficiency in its portfolio companies.

Eric Arnould

General Partner

Clara Audry

General Partner

Pierre Garnier

Managing Partner

Guillaume Girard

Managing Partner

Giacomo Del Grande

CFO

Eoghan Hickey

Managing Partner

Maxime Mallet

General Partner

De Rothschild, Philippe Sereys

Founder and Managing Partner

Laurent Samama

Managing Partner and Impact Officer

Jean Schmitt

Founder, President and Managing Partner

Meriem Smida

Managing Director UK

Stanislas Subra

General Partner

Past deals in EEG

BioSerenity

Venture Round in 2023
BioSerenity is a company focused on enhancing the understanding and treatment of epilepsy and other chronic diseases through innovative, digitally connected devices. These devices facilitate the retrieval and interpretation of electrophysiological signals, including electroencephalograms, electrocardiograms, and polysomnography. By enabling continuous remote monitoring of patients' health data, BioSerenity aims to optimize patient pathways in cardiology, neurology, and sleep disorders. The company also collaborates with the scientific community by providing anonymized data to researchers at the Institut du Cerveau et de la Moelle épinière (ICM), thereby contributing to advancements in epilepsy research and improving future diagnostic methods.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.